In CCA, SMAD4 is among the most frequently mutated genes and has been shown to curtail cell proliferation, tumor progression and drug resistance through TGF-β and Wnt/β-catenin signaling pathways [12, 26]. This evidence concerns the gene SMAD4 and neoplasm.